Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading 0.4% Higher - Here's What Happened

Key Points

• Zealand Pharma A/S shares increased by 0.4% to $79.20, but trading volume was down 42% compared to the average session volume.
• Analysts have overwhelmingly rated Zealand Pharma A/S as a strong buy, with five analysts issuing this rating amidst upgrades from several prominent firms.
• The company's latest earnings report showed an EPS of $16.06, falling short of expectations, alongside a significant revenue miss compared to consensus estimates.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares traded up 0.4% on Wednesday . The company traded as high as $79.20 and last traded at $79.20. 111 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 193 shares. The stock had previously closed at $78.86.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. Zacks Research raised Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a research report on Monday, September 15th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Finally, Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Five investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Strong Buy".

Zealand Pharma A/S Trading Up 0.4%

The stock has a market capitalization of $5.62 billion, a PE ratio of 5.56 and a beta of 0.74. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $65.82 and a 200-day moving average price of $64.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%.The company had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. As a group, equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.